Doug Giordano, MBA

New York, New York, United States
Doug Giordano is currently a Senior VP in Pfizer’s worldwide Business Development Group, responsible for leading Pfizer’s evaluation, negotiation, and execution of product licensing. Partnerships and M&A transactions. Over the past 11 years, Doug has led teams responsible for Pfizer acquisitions, product collaborations/licensing and Pfizer’s IPO/split out of Zoetis. Before joining Pfizer’s WWBD group in 2007, Doug held positions of increasing responsibility within Pfizer’s US Pharmaceuticals commercial strategy and BD team. Doug has been a key contributor to a variety of Pfizer’s transactions and a variety of innovative US commercialization initiatives including the creation and launch of the Pfizer/Microsoft/IBM collaboration, Amicore and the launch of the Pfizer for Living ShareCard and Pfizer Helpful Answers programs. Before his US pharmaceuticals operating role, Doug worked in a mergers and acquisitions role within Pfizer’s Medical Technology Group – playing a key role in Pfizer’s acquisitions, technology licensing, and divestitures activity within Medtech. Prior to his role with the Medical Technology Group, Doug held positions within Pfizer’s US Pharmaceutical Group in finance and global manufacturing. Prior to joining Pfizer, Doug was a consultant at Booz, Allen and Hamilton. oug holds a Bachelor’s Degree in Biomedical Engineering from Duke University and an MBA degree from Cornell University’s Johnson School of Business.
Speaking In
11:00 AM - 12:15 PM
Tuesday, June 4
In recent years, there’s been a scarcity of high quality, revenue-generating biopharma assets. This…